Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30916871 | 0.85 | ALDH1A1 (0.47) | KMT2AMEN1ALDH1A1HPGDKDM4E | |
| SCHEMBL6368861 | 0.85 | ALDH1A1 (0.47) | KMT2AMEN1ALDH1A1HPGDKDM4E | |
| SCHEMBL6289985 | 0.82 | PKM (0.46) | KMT2AMEN1ALDH1A1HPGDKDM4E | |
| SCHEMBL10997396 | 0.80 | KMT2A (0.52) | KMT2AMEN1ALDH1A1HPGDKDM4E | |
| SCHEMBL24608512 | 0.79 | HTT (0.45) | KMT2AMEN1ALDH1A1HPGDKDM4E | |
| SCHEMBL198689 | 0.78 | ALDH1A1 (0.46) | KMT2AMEN1ALDH1A1HPGDKDM4E | |
| SCHEMBL4904367 | 0.78 | KMT2A (0.48) | KMT2AMEN1ALDH1A1HPGDKDM4E | |
| SCHEMBL4057352 | 0.78 | KMT2A (0.46) | KMT2AMEN1ALDH1A1HPGDKDM4E | |
| SCHEMBL22917929 | 0.77 | KMT2A (0.50) | KMT2AMEN1ALDH1A1HPGDKDM4E | |
| SCHEMBL7160198 | 0.77 | MAPT (0.58) | KMT2AMEN1ALDH1A1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250121073-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| US-12150995-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| EP-4271664-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230101353-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-30 | — | — | US | disclosed |
| WO-2022147465-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| US-20160152576-A9 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-20140148436-A1 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-8680114-B2 | AKT protein kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20080070913-A1 | Thieno [ 3,2-b] pyridine-6-carbonitriles and thieno [2,3-b] pyridine-5-carbonitriles as protein kinase inhibitors | BOSCHELLI DIANE H | 2008-03-20 | — | — | US | disclosed |
| US-20080070913-A1 | Thieno [ 3,2-b] pyridine-6-carbonitriles and thieno [2,3-b] pyridine-5-carbonitriles as protein kinase inhibitors | BOSCHELLI DIANE H | 2008-03-20 | — | — | US | disclosed |
| WO-2004048386-A2 | THIENO[3,2-b]PYRIDINE-6-CARBONITRILES AND THIENO[2,3-b]PYRIDINE-5-CARBONITRILES AS PROTEIN KINASE INHIBITORS | WYETH (US) | 2004-06-10 | — | — | WO | disclosed |
| US-20030220365-A1 | Cell adhesion-inhibiting antiinflammatory compounds | STEWART ANDREW O (US) | 2003-11-27 | — | — | US | disclosed |
| US-6579882-B2 | Thieno(2,3-d)pyrimidine derivatives | ABBOTT LABORATORIES | 2003-06-17 | — | — | US | disclosed |
| US-20010020030-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ABBVIE INC. | 2001-09-06 | — | — | US | disclosed |
| US-6232320-B1 | THIENO(2,3-C)PYRIDINE AND 5H-THIENO(2,3-C)PYRAN DERIATIVES | ABBOTT LABORATORIES | 2001-05-15 | — | — | US | disclosed |
| EP-1090009-A2 | CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999062908-A2 | CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 1999-12-09 | — | — | WO | disclosed |
| US-4935431-A | Substituted 7-amino-thienopyridine derivatives as gastric acid secretion inhibitors | SMITHKLINE BECKMAN INTERCREDIT B.V. (NL) | 1990-06-19 | — | — | US | disclosed |
| EP-0334491-A1 | Thienopyridines, process and intermediates for their preparation and pharmaceutical compositions containing them | SMITHKLINE BECKMAN INTERCREDIT B.V. (NL) | 1989-09-27 | — | — | EP | disclosed |
| WO-1989008112-A1 | THIENOPYRIDINES, PREPARATION, INTERMEDIATES AND PHARMACEUTICAL COMPOSITIONS | SMITHKLINE BECKMAN INTERCREDIT B.V. (NL) | 1989-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020030-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ICAM1, VCAM1, EPCAM | KMT2A 4783/4885MEN1 4064/4885ALDH1A1 153/4885 |
| US-20080070913-A1 | Thieno [ 3,2-b] pyridine-6-carbonitriles and thieno [2,3-b] pyridine-5-carbonitriles as protein kinase inhibitors | PKN2, TNNI3K, PKN1 | KMT2A 2822/4885MEN1 1119/4885ALDH1A1 3008/4885 |
| US-20250121073-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KMT2A 445/4885MEN1 4055/4885ALDH1A1 2776/4885 |
| US-12150995-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | KMT2A 445/4885MEN1 4055/4885ALDH1A1 2776/4885 |
| US-20140148436-A1 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | KMT2A 2166/4885MEN1 2997/4885ALDH1A1 3849/4885 |
| US-20030220365-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ICAM1, VCAM1, EPCAM | KMT2A 4783/4885MEN1 4064/4885ALDH1A1 153/4885 |
| US-20160152576-A9 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | KMT2A 2166/4885MEN1 2997/4885ALDH1A1 3849/4885 |
| US-20230101353-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KMT2A 445/4885MEN1 4055/4885ALDH1A1 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.